EMA Set For More Staff Losses & Activity Cuts Next Year
Executive Summary
The latest EMA management board meeting heard an update on the situation regarding Brexit-related staff losses and recruitment, and was told that an additional set of temporary suspensions or reductions in its activities might be necessary from the beginning of 2019.
You may also be interested in...
EMA Updates On Brexit Progress With ‘At-Risk’ Drugs And Staffing Issues
The European Medicines Agency has given an update on its Brexit preparations, including progress with dealing with “at-risk” medicines, staff retention and recruitment issues, and the resumption of some activities that have been temporarily shelved or cut back.
UK Court Ruling Could Impair EMA’s Ability To Do Its Job
A UK judge has said the European Medicines Agency cannot escape the lease on its London premises after Brexit, meaning the agency may have to pay double rent when it moves to Amsterdam. The EMA believes this will affect its ability to carry out its responsibilities as an EU agency.
EU Drug Filings To Fall Slightly In 2019, But Scientific Advice On The Up
The EMA expects initial applications for drug approvals to decline slightly next year, with the budget also down a little because of Brexit uncertainty. The agency's management board reported on its visit to the agency’s future home in Amsterdam.